Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study.

The exposure-response relationship for total Mayo score showed a trend across the treatment groups.

also in 53,322 other papers

There was no apparent treatment effect of abrilumab on stool frequency up to week 12 as compared with the placebo group, but a numerical trend of improvement in rectal bleeding was observed for abrilumab, while numerical trends of improvement in rectosigmoidoscopy and physician’s global assessment score were observed with abrilumab 70 mg and 210 mg.

also in 1,012 other papers